Bayer's Legal Calendar Keeps Sliding, But the Operating Engine Is Finally Firing
Published on 08/13/2026 at 20:11 | Redaktion boerse-global.de
The wait for a definitive answer on Bayer's $7.25 billion Roundup settlement has acquired a new wrinkle: the hearing date itself has become a moving target. Originally slated for September 14, the court session has been pushed back at the joint request of Monsanto and the plaintiffs' bar, with September 10 now floated as the earliest possible alternative.
That procedural shuffle matters more than it might appear. The hearing is the moment when the court decides whether to grant final approval to the sprawling settlement that would channel the bulk of US glyphosate litigation into a single, finite payout. Every delay chips away at the narrative that this overhang is finally being retired.
What complicates the calendar is the fallout from the Supreme Court's June ruling in the Durnell case. That decision strengthened Bayer's hand considerably by narrowing the prospects for plaintiffs pursuing individual claims, but it also triggered a fresh wave of reconsideration. Claimants who had previously filed opt-out notices are now weighing whether to rejoin the settlement, and the court has pushed the hearing back to give those requests time to be processed. The critical variable is simple: how many of those withdrawal requests actually stick. A high volume of reversals would bolster the settlement's integrity; a stubborn residue of opt-outs could invite further judicial scrutiny or demands for sweeteners.
A Quarter That Buys Credibility
While the legal machinery grinds forward, the operating business is delivering the kind of numbers that make the wait more tolerable. Second-quarter revenue rose 2.2 percent on a currency- and portfolio-adjusted basis to €10.872 billion, with adjusted EBITDA climbing 1.9 percent to €2.144 billion. The standout was Crop Science, where adjusted earnings surged 30.2 percent on the back of firmer pricing and lower manufacturing costs.
That operational strength is the foundation on which the legal question is being negotiated — though it does not substitute for an answer. The share price, which briefly flirted with the €50 mark in the wake of the results, now trades at €48.00, roughly 6 percent above its 50-day moving average. The technical picture suggests the recent uptrend remains intact even after a modest pullback, but the stock still sits 11 percent below its 52-week high of €53.86 — a gap that reflects the market's refusal to fully price out litigation risk.
Should investors sell immediately? Or is it worth buying Bayer?
The Analyst Camp Splits
The divergence in professional opinion has become more pronounced. Deutsche Bank Research lifted its price target to €60 on August 5, maintaining a "Buy" rating, while UBS moved to €62 the same day, also with a "Buy." Both houses are effectively signaling that a combination of legal clarity and operational momentum could unlock substantial upside.
Jefferies, however, is not persuaded. The firm kept Bayer at "Hold" with a €46 target on August 10 — below the current trading level — suggesting that the recent rally has already priced in much of the operational improvement. That is a meaningful counterweight to the more enthusiastic calls, and it underscores how much of the bull case now rests on the legal outcome rather than the fundamentals.
There are supporting data points for the optimists. The $5 billion in dollar-denominated bonds placed in July were, according to the company, multiple times oversubscribed — a signal that credit investors remain comfortable with Bayer's financing capacity. The Indian subsidiary also reported a stronger quarterly profit on lower costs, hinting that the cost-saving program is gaining traction across the group. And in pharma, the submission of Kerendia for regulatory approval in China for chronic kidney disease provides a reminder that the pipeline is not standing still.
What Could Still Go Wrong
The bearish scenario is less about outright rejection of the settlement than about death by a thousand delays. This is already the second known postponement of the hearing, and each successive slip feeds the perception that the construction is more fragile than advertised. A third rescheduling would be read as a meaningful negative signal.
There is also the unresolved question of how the court handles plaintiffs who insist on opting out despite the Supreme Court ruling. If the remaining opt-out cohort is too large, the cost calculus of the settlement could unravel, potentially forcing Bayer back into the uncertainty of individual litigation — a scenario with potentially far higher liabilities than the aggregate settlement contemplates.
On the strategic front, the long-discussed question of whether to separate the crop science and pharma businesses remains unanswered. Analysts do not currently expect a near-term breakup, which caps the valuation fantasy in that direction.
Bayer at a turning point? This analysis reveals what investors need to know now.
The Road Ahead
The immediate focal point is clear: the rescheduled hearing, now expected no earlier than September 10. If the opt-out numbers trend downward and the court grants approval, Bayer would clear its single largest legal hurdle in years, and the combination with a recovering Crop Science division would present a picture of simultaneously declining legal and commercial risk.
If the calendar slips again, or if the court signals reservations about the settlement's terms, the uncertainty returns with force — and the Jefferies view gains credibility.
The next concrete milestone after the hearing is the third-quarter report, due November 3, which will offer another opportunity to weigh the operational trajectory — including the expected closing of the Apollo transaction in the contraception business — against the legal overhang. For now, Bayer remains a stock suspended between two forces: an operating recovery that is demonstrably real, and a legal resolution that is tantalizingly close but not yet secured.
Ad
Bayer Stock: New Analysis - 13 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
